What serologic workup is recommended for suspected primary biliary cholangitis and autoimmune hepatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Serologic Workup for Suspected PBC and AIH

For suspected primary biliary cholangitis (PBC), test anti-mitochondrial antibodies (AMA) first, and if negative, proceed with anti-sp100 and anti-gp210 antibodies; for suspected autoimmune hepatitis (AIH), test antinuclear antibodies (ANA), smooth muscle antibodies (SMA), anti-LKM1, and anti-LC1, with PBC-specific antibodies added when cholestatic features are present. 1, 2

Primary Biliary Cholangitis Serologic Algorithm

First-Line Testing

  • AMA (anti-mitochondrial antibodies): This is the primary diagnostic marker for PBC and should be tested first in all suspected cases 1
  • AMA has high sensitivity and specificity for PBC diagnosis
  • When AMA is positive along with cholestatic enzyme pattern, diagnosis is established without need for liver biopsy in most cases

AMA-Negative PBC Testing

If AMA is negative but clinical suspicion remains high:

  • Anti-sp100: Sensitivity 22.7%, specificity 96.5% 1
  • Anti-gp210: Sensitivity 19.7%, specificity 99.0% 1

Critical interpretation points:

  • Anti-gp210 has higher specificity (99%) making it particularly useful as a confirmatory marker 1
  • Anti-sp100 provides modest increase in diagnostic yield but with slightly higher false-positive rate 1
  • These antibodies are confirmatory tests, not screening tests—use only after negative AMA in cholestatic patients 1
  • At 1% disease prevalence, anti-sp100 identifies ~227 true positives per 100,000 tested but generates ~3,465 false positives 1
  • Anti-gp210 identifies ~197 true positives per 100,000 tested with only ~990 false positives 1

Autoimmune Hepatitis Serologic Algorithm

Standard AIH Panel

Type 1 AIH markers:

  • ANA (antinuclear antibodies)
  • SMA (smooth muscle antibodies)

Type 2 AIH markers:

  • Anti-LKM1 (liver kidney microsomal type-1)
  • Anti-LC1 (liver cytosol type 1)

When Cholestatic Features Present

This is a critical clinical decision point: 2

In adults with AIH and biochemical cholestasis:

  • Test PBC-specific autoantibodies (AMA, anti-sp100, anti-gp210) BEFORE any other test 2
  • If PBC antibodies are negative, proceed to magnetic resonance cholangiography to evaluate for PSC 2

In children with AIH:

  • Magnetic resonance cholangiography is recommended for ALL childhood AIH cases regardless of cholestatic enzyme levels 2
  • This is because PSC can manifest with AIH features in children and may evolve over time

Important Clinical Caveats

Subtyping AIH

  • Do not subclassify adult AIH patients based on autoantibody profiles—this is not clinically useful 2
  • The historical AIH-1, AIH-2, AIH-3 classification system should not guide management decisions

Overlap Syndromes

  • PBC-AIH variant requires liver biopsy for diagnosis 3
  • Features can occur sequentially, so periodic re-evaluation of diagnosis is necessary 3
  • The dominant disease should be named first (e.g., AIH/PSC or AIH/PBC when AIH predominates) 2

Timing Considerations

  • In cholestatic presentations, testing for PBC antibodies takes priority over imaging to avoid unnecessary procedures 2
  • Repeat cholangiography may be needed during follow-up if disease activity persists or cholestatic features develop 2

False-Positive Risk Management

The high false-positive rates with anti-sp100 and anti-gp210 are mitigated by:

  • Testing only in highly selected patients already evaluated clinically, biochemically, and with imaging 1
  • UDCA has favorable safety profile, so minimal harm if initiated in rare misclassified patients 1
  • More concerning is the high false-negative rate (773-803 per 100,000 at 1% prevalence), which necessitates liver biopsy when antibodies are negative but suspicion remains high 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.